Genor Biopharma Holdings Limited

SEHK:6998 Stock Report

Market Cap: HK$769.6m

Genor Biopharma Holdings Management

Management criteria checks 2/4

Genor Biopharma Holdings' CEO is Feng Guo, appointed in Apr 2020, has a tenure of 4.58 years. total yearly compensation is CN¥24.29M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 1.35% of the company’s shares, worth HK$10.35M. The average tenure of the management team and the board of directors is 4.4 years and 2.9 years respectively.

Key information

Feng Guo

Chief executive officer

CN¥24.3m

Total compensation

CEO salary percentage18.5%
CEO tenure4.6yrs
CEO ownership1.3%
Management average tenure4.4yrs
Board average tenure2.9yrs

Recent management updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20
Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20
Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29
Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29
We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21
We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05
Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03
We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28
Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10
Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Feng Guo's remuneration changed compared to Genor Biopharma Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥526m

Mar 31 2024n/an/a

-CN¥600m

Dec 31 2023CN¥24mCN¥5m

-CN¥674m

Sep 30 2023n/an/a

-CN¥637m

Jun 30 2023n/an/a

-CN¥599m

Mar 31 2023n/an/a

-CN¥665m

Dec 31 2022CN¥32mCN¥5m

-CN¥730m

Sep 30 2022n/an/a

-CN¥800m

Jun 30 2022n/an/a

-CN¥870m

Mar 31 2022n/an/a

-CN¥868m

Dec 31 2021CN¥41mCN¥5m

-CN¥865m

Compensation vs Market: Feng's total compensation ($USD3.35M) is above average for companies of similar size in the Hong Kong market ($USD233.11K).

Compensation vs Earnings: Feng's compensation has been consistent with company performance over the past year.

CEO

Feng Guo (54 yo)

4.6yrs

Tenure

CN¥24,285,000

Compensation

Dr. Feng Guo Ph D., served as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021 until September 12, 2024.He served as Chairman at Genor Biopharma Holdings Limited since November 02,...

Leadership Team

NamePositionTenureCompensationOwnership
Feng Guo
Chief Executive Officer4.6yrsCN¥24.29m1.35%
HK$ 10.4m
Chengyi Weng
CFO, Company Secretary & Executive Directorno datano data0.074%
HK$ 566.6k
Qibin Liang
Chief Technology Officer3.1yrsno datano data
Xiaojing Zhu
Vice President of Compliance & Administrationno datano datano data
Tong Li
Chief Medical Officer4.3yrsno datano data
Tak Wai Ip
Company Secretary2.4yrsno datano data
Jun Lin
Vice President of Quality Analysis4.8yrsno datano data
Qingtang Duan
General Manager of Yuxi Genor5.3yrsno datano data

4.4yrs

Average Tenure

54yo

Average Age

Experienced Management: 6998's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chengyi Weng
CFO, Company Secretary & Executive Directorless than a yearno data0.074%
HK$ 566.6k
David J. Kerr
Member of Scientific Advisory Board2.9yrsno datano data
Leonard B. Saltz
Member of Scientific Advisory Board2.9yrsno datano data
Wen Chen
Independent Non-Executive Director4.4yrsCN¥420.00kno data
Alex A. Adjei
Member of Scientific Advisory Board2.9yrsno datano data
Edwin Fung
Independent Non-Executive Director4.4yrsCN¥420.00kno data
Dong Lyu
Non Executive Director3yrsno datano data
Zhijian Chen
Chairman of Scientific Advisory Board3.5yrsno datano data
Yangxin Fu
Member of Scientific Advisory Board2.9yrsno datano data
John F. Seymour
Member of Scientific Advisory Board2.9yrsno datano data
John R. Zalcberg
Member of Scientific Advisory Board2.9yrsno datano data
Yi Liu
Non-Executive Director2.3yrsno datano data

2.9yrs

Average Tenure

56yo

Average Age

Experienced Board: 6998's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.